CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)Product type:AdviceProgramme:Medtech innovation briefingPublished: 10 July 2020
Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis (TA276)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 March 2013
Cystic fibrosis: diagnosis and management (NG78)Product type:GuidanceProgramme:NICE guidelinePublished: 25 October 2017
Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (TA988)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 July 2024
Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 November 2012
OxyMask for delivering oxygen therapy (MIB160)Product type:AdviceProgramme:Medtech innovation briefingPublished: 27 September 2018